» Articles » PMID: 32934021

Breast Cancer Cell Detection and Characterization from Breast Milk-Derived Cells

Overview
Journal Cancer Res
Specialty Oncology
Date 2020 Sep 16
PMID 32934021
Citations 9
Authors
Affiliations
Soon will be listed here.
Abstract

Radiologic techniques remain the main method for early detection for breast cancer and are critical to achieve a favorable outcome from cancer. However, more sensitive detection methods to complement radiologic techniques are needed to enhance early detection and treatment strategies. Using our recently established culturing method that allows propagation of normal and cancerous breast epithelial cells of luminal origin, flow cytometry characterization, and genomic sequencing, we show that cancer cells can be detected in breast milk. Cells derived from milk from the breast with cancer were enriched for CD49f/EpCAM, CD44/CD24, and CD271 cancer stem-like cells (CSC). These CSCs carried mutations within the cytoplasmic retention domain of HDAC6, stop/gain insertion in MORF4L1, and deletion mutations within SWI/SNF complex component SMARCC2. CSCs were sensitive to HDAC6 inhibitors, BET bromodomain inhibitors, and EZH2 inhibitors, as mutations in SWI/SNF complex components are known to increase sensitivity to these drugs. Among cells derived from breast milk of additional ten women not known to have breast cancer, two of them contained cells that were enriched for the CSC phenotype and carried mutations in NF1 or KMT2D, which are frequently mutated in breast cancer. Breast milk-derived cells with NF1 mutations also carried copy-number variations in CDKN2C, PTEN, and REL genes. The approach described here may enable rapid cancer cell characterization including driver mutation detection and therapeutic screening for pregnancy/postpartum breast cancers. Furthermore, this method can be developed as a surveillance or early detection tool for women at high risk for developing breast cancer. SIGNIFICANCE: These findings describe how a simple method for characterization of cancer cells in pregnancy and postpartum breast cancer can be exploited as a surveillance tool for women at risk of developing breast cancer.

Citing Articles

N6-methyladenosine-modified TRIM37 augments sunitinib resistance by promoting the ubiquitin-degradation of SmARCC2 and activating the Wnt signaling pathway in renal cell carcinoma.

Luo Q, Dai T, Dong Y, Liang J, Xu Z, Sun Z Cell Death Discov. 2024; 10(1):418.

PMID: 39349442 PMC: 11442835. DOI: 10.1038/s41420-024-02187-w.


Phase separation of phospho-HDAC6 drives aberrant chromatin architecture in triple-negative breast cancer.

Lu B, Qiu R, Wei J, Wang L, Zhang Q, Li M Nat Cancer. 2024; 5(11):1622-1640.

PMID: 39198689 DOI: 10.1038/s43018-024-00816-y.


The challenge of survivors of gynecological carcinomas: a retrospective study on occurrence of second tumors.

Guo J, Wang H, Zou X, Huang R, Liang Z, Liang S Arch Gynecol Obstet. 2024; 310(1):525-533.

PMID: 38709268 DOI: 10.1007/s00404-024-07497-z.


Deciphering a proteomic signature for the early detection of breast cancer from breast milk: the role of quantitative proteomics.

Whitham D, Bruno P, Haaker N, Arcaro K, Pentecost B, Darie C Expert Rev Proteomics. 2024; 21(1-3):81-98.

PMID: 38376826 PMC: 11694492. DOI: 10.1080/14789450.2024.2320158.


Structural and functional insights into the epigenetic regulator MRG15.

Jiang N, Li Y, Jin J, Guo J, Ding Q, Meng D Acta Pharmacol Sin. 2024; 45(5):879-889.

PMID: 38191914 PMC: 11053006. DOI: 10.1038/s41401-023-01211-6.


References
1.
Davis Lynn B, Bodelon C, Pfeiffer R, Yang H, Yang H, Lee M . Differences in Genome-wide DNA Methylation Profiles in Breast Milk by Race and Lactation Duration. Cancer Prev Res (Phila). 2019; 12(11):781-790. PMC: 6825576. DOI: 10.1158/1940-6207.CAPR-19-0169. View

2.
Prasad M, Kumar B, Bhat-Nakshatri P, Anjanappa M, Sandusky G, Miller K . Dual TGFβ/BMP Pathway Inhibition Enables Expansion and Characterization of Multiple Epithelial Cell Types of the Normal and Cancerous Breast. Mol Cancer Res. 2019; 17(7):1556-1570. PMC: 6610652. DOI: 10.1158/1541-7786.MCR-19-0165. View

3.
Ritchie M, Phipson B, Wu D, Hu Y, Law C, Shi W . limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res. 2015; 43(7):e47. PMC: 4402510. DOI: 10.1093/nar/gkv007. View

4.
Buono G, Gerratana L, Bulfoni M, Provinciali N, Basile D, Giuliano M . Circulating tumor DNA analysis in breast cancer: Is it ready for prime-time?. Cancer Treat Rev. 2019; 73:73-83. DOI: 10.1016/j.ctrv.2019.01.004. View

5.
Nagarajan S, Rao S, Sutton J, Cheeseman D, Dunn S, Papachristou E . ARID1A influences HDAC1/BRD4 activity, intrinsic proliferative capacity and breast cancer treatment response. Nat Genet. 2020; 52(2):187-197. PMC: 7116647. DOI: 10.1038/s41588-019-0541-5. View